Research conducted by Florida Cancer Specialists & Research Institute, LLC recently confirmed the effectiveness of a new medication in protecting bone marrow of patients who receive chemotherapy for extensive-stage small cell lung cancer.
Patients with extensive-stage small cell lung cancer (ES-SCLC) who receive trilaciclib appear to experience lower rates of hematologic adverse effects than those who are not treated with the agent.
In their updated guidelines for patients with small cell lung cancer (SCLC), ASCO has recommended the CDK4/6 inhibitor trilaciclib as a myeloid supportive agent for patients with untreated or previously treated extensive-stage SCLC who are receiving chemotherapy or chemoimmunotherapy.
- On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with Sacituzumab Govitecan-Hziy by Over 50% Including Neutropenia, Anemia, and Diarrhea - - Most Enrolled. | May 10, 2023
US FDA approved trilaciclib to offer protection against chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC).